Quanticate Partners with Clinical Ink to Offer ESOURCE Technology for Clinical Trials
Quanticate
, a leading global provider of data-related clinical services recently announced its partnership with Clinical Ink, a US-based company that offers a tablet-based system for collecting electronic source data in clinical trials. The objective of the partnership is to provide a consolidated eSource solution to increase the quality of the data captured and to introduce real-time remote monitoring of data. Quanticate will be utilizing Clinical Ink’s award-winning SureSource® solution that has been proven to speed up the availability of clinical data from clinical research sites.
“As a Clinical Research Organization (CRO) specializing in data-related services, we have been actively working with our customers to develop solutions that can help to provide efficiencies, whilst improving overall quality,” explains David Underwood, Chief Executive Officer at Quanticate. “Our newly launched centralized service provision (CSP) approach is focused on centralizing data to gain additional insight and provide fast access to data within a study and across a portfolio. Our CliQ portal has been developed to offer this insight, and with the use of SureSource by Clinical Ink, access and visualisation of study data will be much quicker also.”
“We are pleased to partner with Quanticate to bring the benefits of eSource to the European clinical trial market,” commented Ed Seguine, CEO of Clinical Ink. “The benefits of our approach to eSource are immediately apparent and, when coupled with Quanticate’s additional services, will provide our customers with real opportunities to simultaneously reduce cost and increase quality in their clinical trial projects.”
In addition to offering traditional EDC and paper options, Quanticate plans to support SureSource as part of an integrated approach to replace EDC with technology that captures source data during a patient visit – no secondary data entry by sites and no source data verification by monitors. Clinical Ink’s SureSource platform has recently been recognized by Gartner Research, Microsoft, and the Society for Clinical Data Management for the “significantly disruptive potential in the area of EDC” that this eSource model represents.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
